|
1
|
Chen J, Liang Y, Hu S, Jiang J, Zeng M, Luo M. Role of ATG7-dependent non-autophagic pathway in angiogenesis. Front Pharmacol 2024; 14:1266311. [PMID: 38269279 PMCID: PMC10806190 DOI: 10.3389/fphar.2023.1266311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Accepted: 12/22/2023] [Indexed: 01/26/2024] Open
Abstract
ATG7, one of the core proteins of autophagy, plays an important role in various biological processes, including the regulation of autophagy. While clear that autophagy drives angiogenesis, the role of ATG7 in angiogenesis remains less defined. Several studies have linked ATG7 with angiogenesis, which has long been underappreciated. The knockdown of ATG7 gene in cerebrovascular development leads to angiogenesis defects. In addition, specific knockout of ATG7 in endothelial cells results in abnormal development of neovascularization. Notably, the autophagy pathway is not necessary for ATG7 regulation of angiogenesis, while the ATG7-dependent non-autophagic pathway plays a critical role in the regulation of neovascularization. In order to gain a better understanding of the non-autophagic pathway-mediated biological functions of the autophagy-associated protein ATG7 and to bring attention to this expanding but understudied research area, this article reviews recent developments in the ATG7-dependent non-autophagic pathways regulating angiogenesis.
Collapse
Affiliation(s)
- Jinxiang Chen
- Basic Medicine Research Innovation Center for Cardiometabolic Diseases, Ministry of Education, Southwest Medical University, Luzhou, Sichuan, China
- School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China
- Key Laboratory of Medical Electrophysiology, Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, Sichuan, China
| | - Yu Liang
- The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China
| | - Shaorun Hu
- Basic Medicine Research Innovation Center for Cardiometabolic Diseases, Ministry of Education, Southwest Medical University, Luzhou, Sichuan, China
- School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China
- Key Laboratory of Medical Electrophysiology, Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, Sichuan, China
| | - Jun Jiang
- Department of General Surgery (Thyroid Surgery), The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China
- Metabolic Vascular Diseases Key Laboratory of Sichuan Province, Luzhou, Sichuan, China
| | - Min Zeng
- Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China
| | - Mao Luo
- Basic Medicine Research Innovation Center for Cardiometabolic Diseases, Ministry of Education, Southwest Medical University, Luzhou, Sichuan, China
- School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China
- Key Laboratory of Medical Electrophysiology, Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, Sichuan, China
| |
Collapse
|
|
2
|
Jin G, Zhang J, Cao T, Zhu H, Shi Y. Celecoxib Reverse Invasion and Metastasis of Gastric Cancer through Lnc_AC006548.28-miR-223-LAMC2 Pathway. COMPUTATIONAL INTELLIGENCE AND NEUROSCIENCE 2022; 2022:6140727. [PMID: 35669642 PMCID: PMC9167023 DOI: 10.1155/2022/6140727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/10/2022] [Revised: 05/03/2022] [Accepted: 05/11/2022] [Indexed: 11/18/2022]
Abstract
Celecoxib, a specific cyclooxygenase-2 (COX-2) inhibitor, is a traditional nonsteroidal antipyretic analgesic and anti-inflammatory drug commonly used in clinic, which has inhibitory effect on colorectal cancer, gastric cancer, and other malignant tumors. This study showed that Celecoxib could significantly reverse the invasion and metastasis of gastric cancer and improved the pathological changes due to GC. We collected the clinical specimens to analyze the correlation between the expression of Lnc_AC006548.28, miR-223, and LAMC2. In the mouse model, Celecoxib can slowdown the growth of GC tumor and the occurrence of this effect may depend on Lnc_AC006548.28-miR-223-LAMC2 pathway, in vitro transfection, RT-PCR, western blot, CCK8, small chamber assay, flow cytometry, and immunohistochemistry to retest the protective effect of celecoxib. Our results showed that Celecoxib could reverse invasion and metastasis of gastric cancer through Lnc_AC006548.28-miR-223-LAMC2 pathway.
Collapse
Affiliation(s)
- Guohua Jin
- Department of Gastroenterology, The First Hospital of Jilin University, Changchun, China
| | - Jianguang Zhang
- Department of Gastroenterology, The First Hospital of Jilin University, Changchun, China
| | - Tingting Cao
- Department of Gastroenterology, The First Hospital of Jilin University, Changchun, China
| | - He Zhu
- Department of Gastroenterology, The First Hospital of Jilin University, Changchun, China
| | - Yang Shi
- Department of Gastroenterology, The First Hospital of Jilin University, Changchun, China
| |
Collapse
|
|
3
|
Mo Y, Wu H, Zheng X, Xu L, Liu L, Liu Z. LncRNA CHRF aggravates myocardial ischemia/reperfusion injury by enhancing autophagy via modulation of the miR-182-5p/ATG7 pathway. J Biochem Mol Toxicol 2021; 35:e22709. [PMID: 33491285 DOI: 10.1002/jbt.22709] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 12/01/2020] [Accepted: 01/08/2021] [Indexed: 11/08/2022]
Abstract
Myocardial ischemia/reperfusion (I/R) injury is a very frequent cardiovascular disease and one of the leading causes of death. Abundant evidence has shown that long noncoding RNAs (lncRNAs) are crucial players in myocardial I/R injury. LncRNA cardiac hypertrophy-related factor (CHRF) has been revealed as an important modulator in cardiac disease. However, the function of CHRF in myocardial I/R injury is unclear. In our current work, we found that the expression of CHRF was upregulated in myocardial I/R injury models. Suppression of CHRF relieved myocardial I/R injury in vivo. In addition, in vitro silencing of CHRF enhanced cell viability and attenuated lactate dehydrogenase activity (LDH) as well as apoptosis in H9C2 cells treated with hypoxia/reoxygenation injury. Autophagy has been studied to play an important role in myocardial I/R injury. Thus, experiments related to autophagy were done, and the results showed that CHRF knockdown decreased autophagy. For the exploration of the regulatory mechanism, we found that CHRF sequestered and negatively regulated miR-182-5p to release its inhibition on ATG7. Findings from rescue assays revealed that ATG7 overexpression could suppress the effects of CHRF silence on cell viability, LDH level, apoptosis, and autophagy. To sum up, our results suggested that CHRF exacerbated myocardial I/R injury by enhancing autophagy via modulation of the miR-182-5p/ATG7 pathway. Therefore, this competing endogenous RNA axis may be a potential therapeutic biomarker for myocardial I/R injury.
Collapse
Affiliation(s)
- Yipeng Mo
- Department of Cardiovascular Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang Province, China
| | - Hairuo Wu
- Department of Cardiovascular Medicine, Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Lianyungang, Jiangsu Province, China
| | - Xiaojun Zheng
- Department of Cardiovascular Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang Province, China
| | - Lin Xu
- Department of Cardiovascular Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang Province, China
| | - Liangliang Liu
- Department of Cardiovascular Medicine, Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Lianyungang, Jiangsu Province, China
| | - Zhen Liu
- Department of Cardiovascular Medicine, Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Lianyungang, Jiangsu Province, China
| |
Collapse
|
|
4
|
Wu M, Chen B, Pan X, Su J. Prognostic Value of Autophagy-related Proteins in Human Gastric Cancer. Cancer Manag Res 2020; 12:13527-13540. [PMID: 33414645 PMCID: PMC7783202 DOI: 10.2147/cmar.s278354] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2020] [Accepted: 11/19/2020] [Indexed: 12/12/2022] Open
Abstract
Purpose Autophagy-related proteins (ATG) play a crucial role in autophagy. Recently, the functions of autophagy in cancer have been gathering attention. However, the prognostic value of ATGs in gastric cancer (GC) has not been explored. Methods The Kaplan–Meier plotter (KM plotter) online database was used to examine the value of ATGs gene expression levels in overall survival (OS) prediction in GC patients with different clinical stage, differentiation, gender, HER2 status, and therapeutic strategy. In vitro experiments applied VE-822, an effective GC treatment, to assess cell migration and proliferation in gastric mucosa epithelial cells, and real-time PCR was used to measure alterations of autophagy-related gene expression. Results High ATG3, ATG4C, ATG5, and ATG10 mRNA levels were associated with good OS, while increased ATG4B, ATG7, ATG12, ATG16L1, and TECPR1 mRNA levels related to unfavorable OS in patients with GC. ATG12 overexpression had different effects on OS due to high levels of heterogeneity. High ATG12 expression was correlated with good OS in female patients with GC and with bad OS for male patients. Additionally, the increased ATG12 expression was more likely to get a satisfactory OS in patients who underwent surgery alone but was associated with poor OS for patients treated with 5-FU adjuvant. In addition, elevated TECPR1 expression was related to favorable OS for patients with poorly differentiated type, while for patients with moderate differentiation, it was relevant to poor OS. The in vitro experiments showed that berzosertib could significantly inhibit the migration and proliferation of human gastric mucosa epithelial cells, and further real-time PCR assessment of ATG expressions partially coincided with the bioinformation analysis above. Conclusion These results indicate that individual ATGs have unique prognostic significance interpreted using Kaplan–Meier plotter analysis and in vitro experiments, and this may help guide clinical therapeutic strategy and promote OS by individualizing therapy for GC patients.
Collapse
Affiliation(s)
- Minmin Wu
- Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, People's Republic of China
| | - Bicheng Chen
- Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, People's Republic of China
| | - Xiaodong Pan
- Department of Transplantation Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, People's Republic of China
| | - Jiadong Su
- Department of Traumatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, People's Republic of China
| |
Collapse
|
|
5
|
Scherr AL, Jassowicz A, Pató A, Elssner C, Ismail L, Schmitt N, Hoffmeister P, Neukirch L, Gdynia G, Goeppert B, Schulze-Bergkamen H, Jäger D, Köhler BC. Knockdown of Atg7 Induces Nuclear-LC3 Dependent Apoptosis and Augments Chemotherapy in Colorectal Cancer Cells. Int J Mol Sci 2020; 21:E1099. [PMID: 32046105 PMCID: PMC7038172 DOI: 10.3390/ijms21031099] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Revised: 01/31/2020] [Accepted: 02/04/2020] [Indexed: 02/06/2023] Open
Abstract
Autophagy is a catabolic process that enables cells to degrade obsolete content and refuel energy depots. In colorectal cancer (CRC) autophagy has been shown to promote tumorigenesis through energy delivery in the condition of uncontrolled proliferation. With this study, we aimed at evaluating whether autophagy sustains CRC cell viability and if it impacts therapy resistance. Initially, a colorectal cancer tissue micro array, containing mucosa (n = 10), adenoma (n = 18) and adenocarcinoma (n = 49) spots, was stained for expression of essential autophagy proteins LC3b, Atg7, p62 and Beclin-1. Subsequently, central autophagy proteins were downregulated in CRC cells using siRNA technology. Viability assays, flow cytometry and immunoblotting were performed and three-dimensional cell culture was utilized to study autophagy in a tissue mimicking environment. In our study we found an upregulation of Atg7 in CRC. Furthermore, we identified Atg7 as crucial factor within the autophagy network for CRC cell viability. Its disruption induced cell death via triggering apoptosis and in combination with conventional chemotherapy it exerted synergistic effects in inducing CRC cell death. Cell death was strictly dependent on nuclear LC3b, since simultaneous knockdown of Atg7 and LC3b completely restored viability. This study unravels a novel cell death preventing function of Atg7 in interaction with LC3b, thereby unmasking a promising therapeutic target in CRC.
Collapse
Affiliation(s)
- Anna-Lena Scherr
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg 69120, Germany; (A.-L.S.); (A.J.); (A.P.); (C.E.); (L.I.); (N.S.); (P.H.); (D.J.)
| | - Adam Jassowicz
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg 69120, Germany; (A.-L.S.); (A.J.); (A.P.); (C.E.); (L.I.); (N.S.); (P.H.); (D.J.)
| | - Anna Pató
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg 69120, Germany; (A.-L.S.); (A.J.); (A.P.); (C.E.); (L.I.); (N.S.); (P.H.); (D.J.)
| | - Christin Elssner
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg 69120, Germany; (A.-L.S.); (A.J.); (A.P.); (C.E.); (L.I.); (N.S.); (P.H.); (D.J.)
| | - Lars Ismail
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg 69120, Germany; (A.-L.S.); (A.J.); (A.P.); (C.E.); (L.I.); (N.S.); (P.H.); (D.J.)
| | - Nathalie Schmitt
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg 69120, Germany; (A.-L.S.); (A.J.); (A.P.); (C.E.); (L.I.); (N.S.); (P.H.); (D.J.)
| | - Paula Hoffmeister
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg 69120, Germany; (A.-L.S.); (A.J.); (A.P.); (C.E.); (L.I.); (N.S.); (P.H.); (D.J.)
| | - Lasse Neukirch
- Clinical Cooperation Unit Applied Tumor Immunity, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg 69120, Germany;
| | - Georg Gdynia
- Institute of Pathology, University Hospital Heidelberg, Heidelberg 69120, Germany; (G.G.); (B.G.)
| | - Benjamin Goeppert
- Institute of Pathology, University Hospital Heidelberg, Heidelberg 69120, Germany; (G.G.); (B.G.)
| | | | - Dirk Jäger
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg 69120, Germany; (A.-L.S.); (A.J.); (A.P.); (C.E.); (L.I.); (N.S.); (P.H.); (D.J.)
| | - Bruno Christian Köhler
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg 69120, Germany; (A.-L.S.); (A.J.); (A.P.); (C.E.); (L.I.); (N.S.); (P.H.); (D.J.)
| |
Collapse
|